Donald A. McGovern Jr. - 04 Sep 2023 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Donald A. McGovern, Jr.
Issuer symbol
ATNF
Transactions as of
04 Sep 2023
Net transactions value
$0
Form type
4
Filing time
06 Sep 2023, 18:28:18 UTC
Previous filing
09 Jun 2023
Next filing
29 Nov 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $0 +25,186 +84% $0.000000 55,285 04 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +15,000 $0.000000 15,000 04 Sep 2023 Common Stock 15,000 $0.6700 Direct F2, F3
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +44,776 $0.000000 44,776 04 Sep 2023 Common Stock 44,776 $0.6700 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued in consideration for serving on the Board of Directors, as Lead Director, Chairman of the Audit Committee, and as a Member of the Compensation Committee and of the Risk, Safety and Regulatory Committee of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2 Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F3 The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
F4 Granted in consideration for serving as Lead Director of the Company during 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.